Early Findings of Patients with Autosomal Dominant Polycystic Kidney Disease Initiating Tolvaptan in the United States: A Claims-Based Analysis
Early Findings of Patients with Autosomal Dominant Polycystic Kidney Disease Initiating Tolvaptan in the United States: A Claims-Based Analysis is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Early Findings of Patients with Autosomal Dominant Polycystic Kidney Disease Initiating Tolvaptan in the United States: A Claims-Based Analysis have?
Early Findings of Patients with Autosomal Dominant Polycystic Kidney Disease Initiating Tolvaptan in the United States: A Claims-Based Analysis has 0 citations in the OpenAlex counts ScholarIQ stores.
When was Early Findings of Patients with Autosomal Dominant Polycystic Kidney Disease Initiating Tolvaptan in the United States: A Claims-Based Analysis published?
Early Findings of Patients with Autosomal Dominant Polycystic Kidney Disease Initiating Tolvaptan in the United States: A Claims-Based Analysis has 2020 year in the ScholarIQ index.
What is the open-access status of Early Findings of Patients with Autosomal Dominant Polycystic Kidney Disease Initiating Tolvaptan in the United States: A Claims-Based Analysis?
Early Findings of Patients with Autosomal Dominant Polycystic Kidney Disease Initiating Tolvaptan in the United States: A Claims-Based Analysis has closed oa status in the ScholarIQ index.
What is the DOI of Early Findings of Patients with Autosomal Dominant Polycystic Kidney Disease Initiating Tolvaptan in the United States: A Claims-Based Analysis?
The DOI for Early Findings of Patients with Autosomal Dominant Polycystic Kidney Disease Initiating Tolvaptan in the United States: A Claims-Based Analysis is on the source record.
What is the OpenAlex record for Early Findings of Patients with Autosomal Dominant Polycystic Kidney Disease Initiating Tolvaptan in the United States: A Claims-Based Analysis?
The OpenAlex for Early Findings of Patients with Autosomal Dominant Polycystic Kidney Disease Initiating Tolvaptan in the United States: A Claims-Based Analysis is on the source record.